Abbott Laboratories Corporation

Icahn School of Medicine at Mount Sinai

Kathy Otis

David J Hawksworth

Robert N Ziemann

Bryan C Tieman

A Scott Muerhoff

Christopher C Marohnic

April Ahlberg

Andrea Branch

Francis Eng

Christopher Marohnic

David Hawksworth

The present disclosure provides detection methods employing HCV core lipid binding domain and DNA binding domain monoclonal antibodies. In certain embodiments, the lipid binding domain monoclonal antibody recognizes an epitope in amino acids 141 to 161 of HCV core protein.

Detection methods employing HCV core lipid and DNA binding domain monoclonal antibodies

The present disclosure provides detection methods employing HCV core lipid binding domain and DNA binding domain monoclonal antibodies or antibody fragments. In certain embodiments, the lipid binding domain monoclonal antibody or antibody fragment recognizes an epitope in amino acids 141 to 161 of HCV core protein and the DNA binding domain antibody or antibody fragment recognizes an epitope in amino acids 95-123 (e.g., in amino acids 99-117) of HCV core protein.

The present invention relates to monoclonal antibodies for the detection of HCV antigen. More specifically, the invention describes antibodies against HCV core antigen lipid binding domain and immunoassay methods, kits and compositions for use in detecting HCV infection.

HCV core lipid binding domain monoclonal antibodies

Growing community of inventors

Abbott Park, IL, United States of America

Kathy Otis